Stephen Opat

11.0k total citations · 2 hit papers
158 papers, 2.7k citations indexed

About

Stephen Opat is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Stephen Opat has authored 158 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pathology and Forensic Medicine, 87 papers in Genetics and 45 papers in Oncology. Recurrent topics in Stephen Opat's work include Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (78 papers) and Immunodeficiency and Autoimmune Disorders (18 papers). Stephen Opat is often cited by papers focused on Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (78 papers) and Immunodeficiency and Autoimmune Disorders (18 papers). Stephen Opat collaborates with scholars based in Australia, United States and New Zealand. Stephen Opat's co-authors include Constantine S. Tam, John F. Seymour, Judith Trotman, Michael Wenger, Carolyn Owen, Wolfram Klapper, Kaspar Rufibach, Tom Moore, Robert Marcus and Michael Herold and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephen Opat

138 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

2017 461 citations Stephen Opat, John F. Seymour et al. profile →
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers

Countries citing papers authored by Stephen Opat

Since Specialization

Citations

This map shows the geographic impact of Stephen Opat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Opat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Opat more than expected).

Fields of papers citing papers by Stephen Opat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Opat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Opat. The network helps show where Stephen Opat may publish in the future.

Co-authorship network of co-authors of Stephen Opat

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Opat. A scholar is included among the top collaborators of Stephen Opat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Opat. Stephen Opat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zanubrutinib in Bing Neel syndrome: efficacy and tolerability 2025 ·Leukemia ·(unknown), (unknown), (unknown), T.W.H. Flinsenberg, (unknown), Marie José Kersten, Jahanzaib Khwaja, Saskia Kuipers, (unknown), (unknown), Stephen Opat, (unknown), (unknown), Sheeba K. Thomas, Alexander F. J. E. Vrancken, Shirley D’Sa, Monique C. Minnema, Josephine M. I. Vos	4
2	Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach 2025 ·Internal Medicine Journal ·(unknown), (unknown), (unknown), George Grigoriadis, Shaun Fleming, (unknown), Pasquale L. Fedele, Michael Löw, Paul Yeh, Michael Gilbertson, (unknown), Gareth P. Gregory, (unknown), (unknown), Zane Kaplan, Sanjeev Chunilal, S. Brown, Stephen Opat, Chong Chyn Chua, Jake Shortt	0
3	BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia. 2024 ·Journal of Clinical Oncology ·(unknown), Stephen Opat, John Hrom, David Kliman, Paula Marlton, (unknown), (unknown), (unknown), Jun Zhang, Haiyi Guo, Steven P. Treon	3
4	BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia 2024 ·Blood ·(unknown), Stephen Opat, John Hrom, David Kliman, Paula Marlton, (unknown), (unknown), (unknown), Jun Zhang, Haiyi Guo, Steven P. Treon	1
5	MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS 2023 ·Hematological Oncology ·Mark Roschewski, David M. Kurtz, Jason R. Westin, Ryan C. Lynch, Stefan Alig, Calum MacAulay, Christian Kuffer, (unknown), André Schultz, Sandra Close, (unknown), Davide Rossi, Stephen Opat, Rodney J. Hicks, Mark Hertzberg, Maximilian Diehn, Wyndham H. Wilson, Ash A. Alizadeh	5
6	Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care 2023 ·Journal of the National Comprehensive Cancer Network ·(unknown), (unknown), Stephen Opat, Jake Shortt, Peter Poon	4
7	Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case–control study 2023 ·Occupational and Environmental Medicine ·Michael K. Odutola, Marina T. van Leeuwen, Fiona Bruinsma, Geza Benke, Michelle C. Turner, Judith Trotman, Jennifer Turner, John F. Seymour, H. Miles Prince, Samuel T. Milliken, Campbell Tiley, Mark Hertzberg, Fernando Roncolato, Stephen Opat, (unknown), Emma Verner, Craig Underhill, Elisabeth Cardis, Graham G. Giles, Claire M. Vajdic	0
8	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort breakdown → 2022 ·Blood ·Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, (unknown), Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, (unknown), Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia	124
9	Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study 2022 ·Cancer Epidemiology ·Michael K. Odutola, Marina T. van Leeuwen, Jennifer Turner, Fiona Bruinsma, John F. Seymour, H. Miles Prince, Samuel T. Milliken, Mark Hertzberg, Judith Trotman, Stephen Opat, (unknown), Fernando Roncolato, Emma Verner, Michael Harvey, Campbell Tiley, Craig Underhill, Geza Benke, Graham G. Giles, Claire M. Vajdic	2
10	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data 2021 ·Blood Advances ·Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhıt Özcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar	107
11	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy 2020 ·Leukemia & lymphoma ·(unknown), (unknown), (unknown), Gareth P. Gregory, Constantine S. Tam, Hang Quach, (unknown), Robin Filshie, Matthew Ku, (unknown), Jake Shortt, Stephen Opat	8
12	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up 2020 ·Blood ·Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Muñoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Atwal, Yiling Yu, William Novotny, Eric Holmgren, (unknown), James Hilger, Jane Huang, Constantine S. Tam	73
13	PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) 2019 ·HemaSphere ·Judith Trotman, Stephen Opat, Paula Marlton, David Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner, Javier Muñoz, Alessandra Tedeschi, Jennifer J. Huang, William Novotny, Medhat Osman, Siminder Atwal, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	3
14	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 2019 ·Blood ·Constantine S. Tam, Tanya Siddiqi, John N. Allan, Thomas J. Kipps, Ian W. Flinn, Bryone J. Kuss, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Ryan Jacobs, Xavier C. Badoux, Paolo Ghia, Juthamas Sukbuntherng, Ahmed Hamed Salem, (unknown), Karl Eckert, Cathy Zhou, Joi Ninomoto, Danelle F. James, William G. Wierda	31
15	Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma 2019 ·Internal Medicine Journal ·Chan Y. Cheah, Stephen Opat, Judith Trotman, Paula Marlton	10
16	Front‐line management of non‐Hodgkin lymphoma in Australia. Part 1: follicular lymphoma 2018 ·Internal Medicine Journal ·Judith Trotman, Chan Y. Cheah, Paula Marlton, Stephen Opat	2
17	Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies 2017 ·Blood ·Gavin Cull, Stephen Opat, Judith Trotman, James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang, Constantine S. Tam	2
18	Disseminated Enteroviral Infection Associated with Obinutuzumab 2015 ·Emerging infectious diseases ·Claire Dendle, Michael Gilbertson, Tony M. Korman, Vera Golder, Eric F. Morand, Stephen Opat	16
19	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma 2009 ·Clinical Cancer Research ·Mark A. Dawson, Stephen Opat, Yamna Taouk, Mark Donovan, (unknown), (unknown), Noemi Horvath, Andrew W. Roberts, H. Miles Prince, Mark Hertzberg, Catriona McLean, Andrew Spencer	25
20	The Recognition of HLA-B27 by Human CD4+ T Lymphocytes 2001 ·The Journal of Immunology ·Louise H. Boyle, Jane Goodall, Stephen Opat, J. S. Hill Gaston	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact